Page 1931 - Williams Hematology ( PDFDrive )

1906 Part XII: Hemostasis and Thrombosis Chapter 112: Platelet Morphology, Biochemistry, and Function 1907

1326. Ma Y, Ashraf MZ, Podrez EA: Scavenger receptor BI modulates platelet reactivity and 1359. Ghebrehiwet B, et al: GC1q-R/p33, a member of a new class of multifunctional and
thrombosis in dyslipidemia. Blood 116(11):1932–1941, 2010. multicompartmental cellular proteins, is involved in inflammation and infection.
1327. Ghosh A, et al: Platelet CD36 mediates interactions with endothelial cell-derived Immunol Rev 180:65–77, 2001.
microparticles and contributes to thrombosis in mice. J Clin Invest 118(5):1934–1943, 1360. Peerschke EI, Ghebrehiwet B: Platelet receptors for the complement component C1q:
2008. Implications for hemostasis and thrombosis. Immunobiology 199(2):239–249, 1998.
1328. Hajjar DP, Gotto AM: Targeting CD36: Modulating inflammation and atherogenesis. 1361. Peerschke EIB, Ghebrehiwet B: Human blood platelets possess specific binding sites
Curr Atheroscler Rep 5(3):155–156, 2003. for C1q. J Immunol 138:1537–1541, 1987.
1329. Hirano K, et al: Pathophysiology of human genetic CD36 deficiency. Trends Cardio- 1362. Ghebrehiwet B, et al: Isolation, cDNA cloning, and overexpression of a 33-kD cell
vasc Med 13(4):136–141, 2003. surface glycoprotein that binds to the globular “heads” of C1q. J Exp Med 179(6):
1330. Pravenec M, Kurtz TW: Genetics of Cd36 and the hypertension metabolic syndrome. 1809–1821, 1994.
Semin Nephrol 22(2):148–153, 2002. 1363. Herwald H, et al: Isolation and characterization of the kininogen-binding protein
1331. Su X, Abumrad NA: Cellular fatty acid uptake: A pathway under construction. Trends p33 from endothelial cells. Identity with the gC1q receptor. J Biol Chem 271(22):
Endocrinol Metab 20(2):72–77, 2009. 13040–13047, 1996.
1332. Asch AS, et al: Isolation of the thrombospondin membrane receptor. J Clin Invest 1364. Nepomuceno RR, Tenner AJ: C1qRP, the C1q receptor that enhances phagocytosis, is
79:1054–1061, 1987. detected specifically in human cells of myeloid lineage, endothelial cells, and platelets.
1333. Diaz-Ricart M, et al: Antibodies to CD36 (GPIV) inhibit platelet adhesion to sub- J Immunol 160(4):1929–1935, 1998.
endothelial surfaces under flow conditions. Arterioscler Thromb Vasc Biol 16(7):883– 1365. Peerschke EI, Reid KB, Ghebrehiwet B: Platelet activation by C1q results in the induc-
888, 1996. tion of alpha IIb/beta 3 integrins (GPIIb-IIIa) and the expression of P-selectin and
1334. Tandon NN, Kralisz U, Jamieson GA: Identification of glycoprotein IV (CD36) as a procoagulant activity. J Exp Med 178(2):579–587, 1993.
primary receptor for platelet-collagen adhesion. J Biol Chem 264:7576–7583, 1989. 1366. Skoglund C, et al: C1q induces a rapid up-regulation of P-selectin and modulates col-
1335. Saelman EU, et al: Platelet adhesion to collagen and endothelial cell matrix under lagen- and collagen-related peptide-triggered activation in human platelets. Immuno-
flow conditions is not dependent on platelet glycoprotein IV. Blood 83(11):3240–3244, biology 215(12):987–995, 2010.
1994. 1367. Peerschke EIB: Platelet membrane receptors for the complement component C1q.
1336. Wun T, et al: Platelet-erythrocyte adhesion in sickle cell disease. J Investig Med Semin Hematol 31:320–328, 1994.
47(3):121–127, 1999. 1368. Peerschke EIB, et al: Platelet activation by C1q results in the induction of αIIbβ3 integ-
1337. Valiyaveettil M, et al: Oxidized high-density lipoprotein inhibits platelet activation rins (GPIIb-IIIa) and the expression of P-selectin and procoagulant activity. J Exp Med
and aggregation via scavenger receptor BI. Blood 111(4):1962–1971, 2008. 178:579–587, 1993.
1338. Chadwick AC, Sahoo D: Functional genomics of the human high-density lipoprotein 1369. Jiang J, et al: Crystal structure of human p32, a doughnut-shaped acidic mitochondrial
receptor scavenger receptor BI: An old dog with new tricks. Curr Opin Endocrinol matrix protein. Proc Natl Acad Sci U S A 96(7):3572–3577, 1999.
Diabetes Obes 20(2):124–131, 2013. 1370. Metzelaar MJ, et al: Identification of a 33-Kd protein associated with the alpha-
1339. Choi WS, Jeon OH, Kim DS: CD40 ligand shedding is regulated by interaction granule membrane (GMP-33) that is expressed on the surface of activated platelets.
between matrix metalloproteinase-2 and platelet integrin alpha(IIb)beta(3). J Thromb Blood 79(2):372–379, 1992.
Haemost 8(6):1364–1371, 2010. 1371. Damas C, et al: The 33-kDa platelet alpha-granule membrane protein (GMP-33) is
1340. Heeschen C, et al: Soluble CD40 ligand in acute coronary syndromes. N Engl J Med an N-terminal proteolytic fragment of thrombospondin. Thromb Haemost 86(3):
348(12):1104–1111, 2003. 887–893, 2001.
1341. Andre P, et al: Platelet-derived CD40L: The switch-hitting player of cardiovascular 1372. Rosenstein Y, et al: CD43, a molecule defective in Wiskott-Aldrich syndrome, binds
disease. Circulation 106(8):896–899, 2002. ICAM-1. Nature 354(6350):233–235, 1991.
1342. Aukrust P, Damas JK, Solum NO: Soluble CD40 ligand and platelets: Self-perpetu- 1373. Koupenova M, Mick E, Mikhalev E, et al: Sex differences in platelet toll-like receptors
ating pathogenic loop in thrombosis and inflammation? J Am Coll Cardiol 43(12): and their association with cardiovascular risk factors. Arterioscler Thromb Vasc Biol
2326–2328, 2004. 35(4):1030–1037, 2015.
1343. Jin R, Yu S, Song Z, et al: Soluble CD40 ligand stimulates CD40-dependent activation 1374. Panigrahi S, et al: Engagement of platelet toll-like receptor 9 by novel endogenous lig-
of the β2 integrin Mac-1 and protein kinase C zeda (PKCζ) in neutrophils: Implica- ands promotes platelet hyperreactivity and thrombosis. Circ Res 112(1):103–112, 2013.
tions for neutrophil-platelet interactions and neutrophil oxidative burst. PLoS One 1375. Rivadeneyra L, et al: Regulation of platelet responses triggered by Toll-like receptor
8(6):e64631, 2013. 2 and 4 ligands is another non-genomic role of nuclear factor-kappaB. Thromb Res
1344. Varo N, de Lemos JA, Libby P, et al: Soluble CD40L: Risk prediction after acute coro- 133(2):235–243, 2014.
nary syndromes. Circulation 108(9):1049–1052, 2003. 1376. Semple JW, et al: Platelet-bound lipopolysaccharide enhances Fc receptor-mediated
1345. Cipollone F, et al: Preprocedural level of soluble CD40L is predictive of enhanced phagocytosis of IgG-opsonized platelets. Blood 109(11):4803–4805, 2007.
inflammatory response and restenosis after coronary angioplasty. Circulation 1377. Zhang G, et al: Lipopolysaccharide stimulates platelet secretion and potentiates plate-
108(22):2776–2782, 2003. let aggregation via TLR4/MyD88 and the cGMP-dependent protein kinase pathway. J
1346. Lievens D, et al: Platelet CD40L mediates thrombotic and inflammatory processes in Immunol 182(12):7997–8004, 2009.
atherosclerosis. Blood 116(20):4317–4327, 2010. 1378. Stahl AL, et al: Lipopolysaccharide from enterohemorrhagic Escherichia coli binds to
1347. Pamukcu B, et al: The CD40-CD40L system in cardiovascular disease. Ann Med platelets through TLR4 and CD62 and is detected on circulating platelets in patients
43(5):331–340, 2011. with hemolytic uremic syndrome. Blood 108(1):167–176, 2006.
1348. Andre P, et al: CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mech- 1379. Cognasse F, et al: Toll-like receptor 4 ligand can differentially modulate the release of
anism. Nat Med 8(3):247–252, 2002. cytokines by human platelets. Br J Haematol 141(1):84–91, 2008.
1349. Inwald DP, et al: CD40 is constitutively expressed on platelets and provides a novel 1380. Scott T, Owens MD: Thrombocytes respond to lipopolysaccharide through Toll-like
mechanism for platelet activation. Circ Res 92(9):1041–1048, 2003. receptor-4, and MAP kinase and NF-kappaB pathways leading to expression of inter-
1350. Prasad KS, et al: Soluble CD40 ligand induces beta3 integrin tyrosine phosphoryla- leukin-6 and cyclooxygenase-2 with production of prostaglandin E2. Mol Immunol
tion and triggers platelet activation by outside-in signaling. Proc Natl Acad Sci U S A 45(4):1001–1008, 2008.
100(21):12367–12371, 2003. 1381. Stark RJ, Aghakasiri N, Rumbaut RE: Platelet-derived Toll-like receptor 4
1351. Urbich C, et al: CD40 ligand inhibits endothelial cell migration by increasing produc- (Tlr-4) is sufficient to promote microvascular thrombosis in endotoxemia. PLoS One
tion of endothelial reactive oxygen species. Circulation 106(8):981–986, 2002. 7(7):e41254, 2012.
1352. Czapiga M, Kirk AD, Lekstrom-Himes J: Platelets deliver costimulatory signals to 1382. Ren MP, et al: Endothelial cells but not platelets are the major source of Toll-like
antigen-presenting cells: A potential bridge between injury and immune activation. receptor 4 in the arterial thrombosis and tissue factor expression in mice. Am J Physiol
Exp Hematol 32(2):135–139, 2004. Regul Integr Comp Physiol 307(7):R901–R907, 2014.
1353. Elzey BD, et al: Platelet-mediated modulation of adaptive immunity. A communica- 1383. Gould TJ, Vu TT, Swystun LL, et al: Neutrophil extracellular traps promote thrombin
tion link between innate and adaptive immune compartments. Immunity 19(1):9–19, generation through platelet-dependent and platelet-independent mechanisms. Arte-
2003. rioscler Thromb Vasc Biol 34(9):1977–1984, 2014.
1354. Ahmad R, et al: Activated human platelets express Fas-L and induce apoptosis in 1384. Akbiyik F, et al: Human bone marrow megakaryocytes and platelets express
Fas-positive tumor cells. J Leukoc Biol 69(1):123–128, 2001. PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and
1355. Crist SA, et al: Expression of TNF-related apoptosis-inducing ligand (TRAIL) in thromboxanes. Blood 104(5):1361–1368, 2004.
megakaryocytes and platelets. Exp Hematol 32(11):1073–1081, 2004. 1385. Ray DM, et al: Peroxisome proliferator-activated receptor gamma and retinoid X
1356. Otterdal K, et al: Platelet-derived LIGHT induces inflammatory responses in endo- receptor transcription factors are released from activated human platelets and shed in
thelial cells and monocytes. Blood 108(3):928–935, 2006. microparticles. Thromb Haemost 99(1):86–95, 2008.
1357. Saftig P, Schroder B, Blanz J: Lysosomal membrane proteins: Life between acid and 1386. Ali FY, et al: Role of nuclear receptor signaling in platelets: Antithrombotic effects of
neutral conditions. Biochem Soc Trans 38(6):1420–1423, 2010. PPARbeta. FASEB J 20(2):326–328, 2006.
1358. Silverstein RL, Febbraio M: Identification of lysosome-associated membrane 1387. Borchert M, et al: Review of the pleiotropic effects of peroxisome proliferator-
protein-2 as an activation-dependent platelet surface glycoprotein. Blood 80(6): activated receptor gamma agonists on platelet function. Diabetes Technol Ther 9(5):
1470–1475, 1992. 410–420, 2007.

Kaushansky_chapter 112_p1829-1914.indd 1906 17/09/15 3:30 pm